The National Meningitis Association (NMA) today announced the launch of a new educational initiative in collaboration with Sanofi Pasteur, the vaccines division of Sanofi, about the importance of the Centers for Disease Control and Prevention’s (CDC’s) recommended second dose of the meningococcal meningitis vaccine (MenACWY) for adolescents at age 16. The 16 Vaccine (The16Vaccine.org) aims to educate parents about the importance of this critical second dose of MenACWY, which helps protect teens against meningococcal meningitis during the period when they are at increased risk.
To view the multimedia release go to:
https://www.multivu.com/players/English/8385951-national-meningitis-association-the-16-vaccine/
A new national survey shows most preteens and teens engage in day-to-day activities that may put them at risk of contracting meningococcal meningitis, a rare, but serious bacterial infection that can cause meningitis and take the life of an otherwise healthy child in just a single day. The National Association of School Nurses (NASN), in collaboration with Sanofi Pasteur, conducted the survey as part of its Voices of Meningitis back-to-school vaccination awareness initiative.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/voicesofmeningitis/50125/
Actress and mother of two Sarah Michelle Gellar is joining March of Dimes and Sanofi Pasteur on the Sounds of Pertussis® Campaign to help raise awareness about pertussis, also known as whooping cough, and the importance of adult vaccination. Pertussis is on the rise across the U.S., and infants and young children may be most vulnerable.
To view Multimedia News Release, go to http://www.multivu.com/players/English/61367-sanofi-pasteur-sounds-of-pertussis/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
La osteoartritis (OA) es una de las primeras 10 causas de invalidez total en México, lo que incrementa la carga económica y social del país, siendo las rodillas una de las articulaciones más frecuentemente afectadas por esta enfermedad, con una prevalencia de 10% en hombres y 13% en mujeres de 60 años de edad1. Especialistas en la materia, indican que es muy importante crear conciencia sobre el cuidado de estas articulaciones desde edades tempranas. Con este objetivo y para generar un mayor conocimiento de este padecimiento, se desarrolló la campaña “Rodillas sin dolor”.
Para ver los activos de multimedia asociados con este comunicado, haga clic en: http://www.multivu.com/players/English/7099651-sanofi-rodillas-sin-dolor-lesiones-tempranas-osteoartritis/
Every spring, allergies take control of the lives of millions of Americans, affecting their work, their family time and even how well they sleep at night. Something else affects those millions of allergy sufferers, according to a new survey: big misconceptions about allergies that may keep people from getting needed relief.
To help put those misconceptions about allergies to rest, Sanofi is teaming up with science educator and television personality Adam Savage, along with allergist Dr. Neeta Ogden, to dispel them with credible information. The goal: help the 50 million allergy sufferers in America get the facts they need to understand and treat their allergies and take back control of their lives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8255452-sanofi-allergy-misconceptions-facts-adam-savage/
Voices of Meningitis, a public health initiative of the National Association of School Nurses (NASN) in collaboration with Sanofi Pasteur, announced today the launch of Get in the Game: Keeping Teens Healthy, a new program to help educate parents on the danger and prevention of meningococcal disease. Get in the Game will help raise awareness about the serious consequences of the disease and motivate parents to speak with their children's health care professional about vaccinating against meningococcal disease in advance of each sports season.
To view Multimedia News Release, go to http://www.multivu.com/players/English/61652-voices-of-meningitis-get-in-the-game/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today the initiation of its Phase III clinical program called Cdiffense to evaluate the safety, immunogenicity and efficacy of an investigational vaccine for the prevention of primary symptomatic Clostridium difficile infection (CDI). Clostridium difficile (C. diff) is a potentially life-threatening, spore-forming bacterium that causes intestinal disease. The risk of C. diff increases with age, antibiotic treatment and time spent in hospitals or nursing homes, where multiple cases can lead to outbreaks. The investigational vaccine is designed to help protect at-risk individuals from C. diff, which is emerging as a leading cause of life-threatening, healthcare-associated infections (HAIs) worldwide.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/62652-sanofi-pasteur-initiates-phase-iii-study-of-investigational-vaccine
Nancy Lieberman, basketball hall of famer, coach and mom, has teamed up with Sanofi’s consumer healthcare division Chattem Inc. to introduce a new, more effective player on the over-the-counter (OTC) allergy medication roster, Nasacort Allergy 24HR Nasal Spray. Now available in stores nationwide, Nasacort Allergy 24HR is different than other currently available OTC allergy medications. It puts the “Full ‘Cort Press” on the full range of nasal allergy symptoms for 24 hours with a once daily dose. Nasacort Allergy 24HR is the first and only medicine in its class to be available at full prescription strength without the need for a prescription.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7122351-basketball-hall-of-famer-nancy-lieberman-nasacort-allergy-24hr
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
Music icon Barry Manilow today revealed his long struggle to manage a serious heart disease called atrial fibrillation (AFib). He has joined with Sanofi US to kick-off Get Back in Rhythm™, a national education campaign to raise awareness about AFib, and to encourage people to learn more about all the risks of AFib and the importance of keeping the heart in rhythm.
Today, approximately 2.5 million Americans have AFib and that number is expected to grow to 12 million by 2050. A serious heart disease that causes the heart to race and beat out of rhythm, AFib can lead to permanent heart damage, heart attack, heart failure, stroke and death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51813-get-back-in-rhythm-barry-manilow-afib-awareness
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of Fluzone® (Influenza Vaccine) for the 2016-2017 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA) for shipment. This represents the first of more than 65 million total doses of seasonal influenza vaccine manufactured by Sanofi Pasteur that will be delivered to U.S. health care providers and pharmacies beginning in July and continuing throughout the remainder of the year. Sanofi Pasteur plans to increase its supply to respond to the shifting pediatric public health needs.
Seasonal influenza activity typically occurs between October and May and peaks between December and February. However, influenza activity peaked noticeably late last season occurring in early March 2016.1 Influenza seasons are always unpredictable as new influenza strains emerge and strain activity fluctuates throughout the year, making timely vaccination even more important to help protect against the virus, especially for seniors, young children and infants six months of age and older.
To view the multimedia release go to:
http://www.multivu.com/players/English/7842051-sanofi-pasteur-influenza-vaccine/
